文献速递妇产影像儿科影像US

单绒毛膜双胎妊娠合并选择性胎儿生长受限:依据管理方式的围产期结局系统综述与Meta分析

Perinatal outcome of monochorionic twin pregnancy complicated by selective fetal growth restriction according to management: systematic review and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2019-01-01

该系统综述与Meta分析纳入16项观察性研究共786例单绒毛膜双胎妊娠,按Gratacós分型评估期待管理、激光治疗或选择性减胎对围产期结局的影响。I型期待管理围产期结局良好;II型或III型接受胎儿镜激光消融者死亡率高于期待管理但发病率较低;选择性减胎数据稀少,缺乏随机对照试验证据,产前管理应个体化。

要点

  • I型sFGR期待管理时胎儿宫内死亡发生率3.1%(95%CI 1.1-5.9%),97.9%双胎无神经系统并发症存活。
  • II型sFGR激光治疗胎儿宫内死亡44.3%(95%CI 22.2-67.7%),高于期待管理的16.6%(95%CI 6.9-29.5%)。
  • 选择性减胎数据稀少,结论需结合Gratacós分型、孕龄及多普勒异常程度个体化评估。

核心结论

  • I型sFGR期待管理围产期结局良好,对大多数病例是最合理的管理策略。
  • II型或III型sFGR接受胎儿镜激光消融者死亡率高于期待管理但发病率较低,支持在远离新生儿存活期的孕龄使用胎儿治疗。
  • 选择性减胎后的结局数据稀少;鉴于缺乏随机对照试验证据,sFGR的产前管理应根据诊断时孕龄、生长不一致严重程度和多普勒异常程度个体化。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE、CINAHL、ClinicalTrials.gov和Cochrane Library数据库。
  • 纳入16项观察性研究,共786例单绒毛膜双胎妊娠,仅纳入按Gratacós分型(I、II或III型)分类的sFGR妊娠。
  • 主要结局为死亡率,包括单胎和双胎宫内死亡、新生儿死亡和围产期死亡;采用比例Meta分析。

诊断标准与关键数值

  • I型sFGR期待管理:胎儿宫内死亡3.1%(95%CI 1.1-5.9%),97.9%(95%CI 93.6-99.9%)双胎无神经系统并发症存活。
  • I型sFGR激光治疗:胎儿宫内死亡16.7%(95%CI 0.4-64.1%);选择性减胎:共存胎儿宫内死亡0%(95%CI 0-34.9%),存活者无神经系统并发症证据。
  • II型sFGR期待管理:胎儿宫内死亡16.6%(95%CI 6.9-29.5%),新生儿死亡6.4%(95%CI 0.2-28.2%),89.3%(95%CI 71.8-97.7%)双胎无神经系统损害存活。
  • II型sFGR激光治疗:胎儿宫内死亡44.3%(95%CI 22.2-67.7%),无病例发生 morbidity,存活者无神经系统并发症;选择性减胎:共存胎儿宫内死亡5.0%(95%CI 0.03-20.5%),新生儿死亡3.7%(95%CI 0.2-11.1%),90.6%(95%CI 42.3-94.3%)存活共存胎儿无神经系统并发症。
  • III型sFGR期待管理:胎儿宫内死亡13.2%(95%CI 7.2-20.5%),新生儿死亡6.8%(95%CI 0.7-18.6%),61.9%(95%CI 38.4-81.9%)双胎无神经系统并发症存活;激光治疗:胎儿宫内死亡32.9%(95%CI 20.9-46.2%),存活双胎均无神经系统并发症;选择性减胎:共存胎儿新生儿死亡5.2%(95%CI 0.8-12.8%),98.8%(95%CI 93.9-99.9%)无神经系统并发症存活。

临床应用与阅片要点

  • 阅片和报告sFGR病例时应明确Gratacós分型(I、II或III型),因其与不同管理方式的围产期结局相关。
  • 评估多普勒异常程度和生长不一致严重程度,结合诊断时孕龄为个体化产前管理提供依据。
  • II型或III型sFGR激光治疗后死亡率较高但存活者发病率较低,报告时需注意区分死亡与神经系统并发症结局。

局限性

  • 纳入研究均为观察性研究,缺乏随机对照试验证据。
  • 选择性减胎后的结局数据稀少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To explore the impact of severity and management (expectant, laser treatment or selective reduction) on perinatal outcome of monochorionic twin pregnancies complicated by selective fetal growth restriction (sFGR).

METHODS: MEDLINE, EMBASE, CINAHL, ClinicalTrials.gov and The Cochrane Library databases were searched for studies on outcome following expectant management, laser treatment or selective reduction in monochorionic twin pregnancies complicated by sFGR. Only pregnancies affected by sFGR and categorized according to the Gratacós classification (Type I, II or III) were included. The primary outcome was mortality, including single and double intrauterine (IUD), neonatal (NND) and perinatal deaths. Secondary outcomes were neonatal morbidity, abnormal postnatal brain imaging, intraventricular hemorrhage, periventricular leukomalacia, respiratory distress syndrome, admission to neonatal intensive care unit and survival free from neurological complications (intact survival). Meta-analyses of proportions were used to analyze the extracted data according to management, severity of sFGR and fetal size (smaller vs larger twin).

RESULTS: Sixteen observational studies (786 monochorionic twin pregnancies) were included. In pregnancies complicated by Type-I sFGR managed expectantly, IUD occurred in 3.1% (95% CI, 1.1-5.9%) of fetuses and 97.9% (95% CI, 93.6-99.9%) of twins had intact survival. In pregnancies complicated by Type-I sFGR treated using laser therapy, IUD occurred in 16.7% (95% CI, 0.4-64.1%) of fetuses and, in those treated using selective reduction, IUD occurred in 0% (95% CI, 0-34.9%) of cotwins, with no evidence of neurological complications in the survivors. In pregnancies complicated by Type-II sFGR managed expectantly, IUD occurred in 16.6% (95% CI, 6.9-29.5%) and NND in 6.4% (95% CI, 0.2-28.2%) of fetuses, and 89.3% (95% CI, 71.8-97.7%) of twins survived without neurological compromise. In Type-II sFGR pregnancies treated using laser therapy, IUD occurred in 44.3% (95% CI, 22.2-67.7%) of fetuses, while none of the affected cases experienced morbidity and survivors were free of neurological complications. Of pregnancies undergoing selective reduction, IUD of the cotwin occurred in 5.0% (95% CI, 0.03-20.5%) and NND in 3.7% (95% CI, 0.2-11.1%), and 90.6% (95% CI, 42.3-94.3%) of surviving cotwins were free from neurological complications. In pregnancies complicated by Type-III sFGR managed expectantly, IUD occurred in 13.2% (95% CI, 7.2-20.5%) and NND in 6.8% (95% CI, 0.7-18.6%) of fetuses, and 61.9% (95% CI, 38.4-81.9%) of twins had intact survival. In pregnancies complicated by Type-III sFGR treated with laser therapy, IUD occurred in 32.9% (95% CI, 20.9-46.2%) of fetuses and all surviving twins were without neurological complications. Finally, in pregnancies with Type-III sFGR treated with selective reduction, NND occurred in 5.2% (95% CI, 0.8-12.8%) of cotwins and 98.8% (95% CI, 93.9-99.9%) had intact survival.

CONCLUSION: Type-I sFGR is characterized by good perinatal outcome when managed expectantly, which represents the most reasonable management strategy for the large majority of affected cases. Pregnancies complicated by Type-II or -III sFGR treated with fetoscopic laser ablation have a higher rate of mortality but lower rate of morbidity compared with those managed expectantly, supporting the use of fetal therapy at gestations remote from neonatal viability. Data on outcome following selective reduction are scarce. In view of the lack of evidence from randomized controlled trials, prenatal management of sFGR should be individualized according to gestational age at diagnosis, severity of growth discordance and magnitude of Doppler anomalies. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Townsend R, D'Antonio F, Sileo FG, et al. Perinatal outcome of monochorionic twin pregnancy complicated by selective fetal growth restriction according to management: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2019. PMID: 30207011. doi:10.1002/uog.20114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。